To assess the impact of a new anti-BMP small molecule (SM) as oral EAE treatment, studying its effects on disease disability, myelination, axonal integrity, astrogenesis, in vitro BMP signaling and pharmacokinetics
No takes yet. Share an insight, caveat, or question.
Golan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: